Polyphenol

Epigallocatechin gallate (EGCG) for Colon Cancer

Q: Are there any other experiments that have been conducted utilizing Epigallocatechin gallate (EGCG)?

Currently, 3 clinical trials are in-progress that investigate Epigallocatechin gallate (EGCG) with none being at the Phase 3 stage. Despite this, there are a total of 296 research facilities across the world conducting these studies, most notably in Fort Collins, Colorado.

Q: Are there any available opportunities for participants in this experiment?

Affirmative. As per the information on clinicaltrials.gov, this study is actively seeking participants and was initially listed in January 31st 2017 with its most recent update being December 13th 2021. The sample size consists of 50 patients from a single location.

Q: How many people is this study recruiting?

Affirmative. The clinical trial registry hosted on clinicaltrials.gov discloses that the study, which was first posted on January 31st 2017, is now actively recruiting 50 participants from 1 different medical site.

Phase < 1

Recruiting

Led By Sukeshi Patel, MD

Research Sponsored by The University of Texas Health Science Center at San Antonio

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Must not have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up1 year

Awards & highlights

No Placebo-Only Group

Study Summary

This trial is for patients with colon or rectal cancer who haven't received any treatment yet. If they're eligible for surgery, they'll be enrolled and given the chance to either have surgery alone or surgery with a new type of chemotherapy.

Eligible Conditions

Colon Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in methylation from baseline when compared to the control arm

Side effects data

From 2022 Phase 1 trial • 39 Patients • NCT04177693

Headaches

Migraine after vaccine

Diarrhea

100%

80%

60%

40%

20%

Study treatment Arm

EGCG Daily Alone.

EGCG With Clomiphene Citrate

EGCG With Letrozole

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: epigallocatechin gallate (EGCG)Experimental Treatment1 Intervention

Patients randomized to the EGCG arm, will start EGCG within 4-12 weeks of surgery and take EGCG 450 mg PO twice a day.

Group II: Observation OnlyActive Control1 Intervention

Standard of care surgical resection followed by standard of care colonoscopy at year.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Green tea leaf

Not yet FDA approved

Do I qualify?Apply below to find out

Find a site

Who is running the clinical trial?

The University of Texas Health Science Center at San AntonioLead Sponsor

431 Previous Clinical Trials

83,194 Total Patients Enrolled

Sukeshi Patel, MD5.01 ReviewsPrincipal Investigator - CTRC (Cancer Therapy and Research Center) at UTHSCSA

The University of Texas Health Science Center at San Antonio

Media Library

Colon Cancer Research Study Groups: epigallocatechin gallate (EGCG), Observation Only

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any other experiments that have been conducted utilizing Epigallocatechin gallate (EGCG)?

"Currently, 3 clinical trials are in-progress that investigate Epigallocatechin gallate (EGCG) with none being at the Phase 3 stage. Despite this, there are a total of 296 research facilities across the world conducting these studies, most notably in Fort Collins, Colorado."

Answered by AI

Are there any available opportunities for participants in this experiment?

"Affirmative. As per the information on clinicaltrials.gov, this study is actively seeking participants and was initially listed in January 31st 2017 with its most recent update being December 13th 2021. The sample size consists of 50 patients from a single location."

Answered by AI

How many people is this study recruiting?

"Affirmative. The clinical trial registry hosted on clinicaltrials.gov discloses that the study, which was first posted on January 31st 2017, is now actively recruiting 50 participants from 1 different medical site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients

Sukeshi Patel 2017. "Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02891538.